AngioDynamics Lifts FY2026 Outlook After Strong Q2 Driven by Med Tech Gains
Raised guidance reflects Med Tech momentum, with a new NanoKnife CPT code bolstering reimbursement.
Overview
- Q2 revenue rose 8.8% year over year on a pro forma basis, with Med Tech up 13%.
- Adjusted EBITDA nearly doubled versus last year, and the company generated positive cash flow.
- Auryon posted an 18th consecutive quarter of double-digit growth as hospital penetration increased and market share expanded.
- Management highlighted commercial and regulatory traction for Mechanical Thrombectomy and noted a newly effective CPT code that supports NanoKnife adoption.
- Results exclude divested and discontinued businesses, and the company emphasized non-GAAP and pro forma measures while directing investors to SEC filings for risk disclosures.